Compare ALPX & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALPX | NBP |
|---|---|---|
| Founded | 2026 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 149.2M |
| IPO Year | 2026 | 2019 |
| Metric | ALPX | NBP |
|---|---|---|
| Price | $10.01 | $0.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 99.5K | ★ 470.8K |
| Earning Date | N/A | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $1.01 |
| 52 Week High | $10.00 | $5.19 |
| Indicator | ALPX | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 24.90 |
| Support Level | $9.95 | N/A |
| Resistance Level | $9.97 | $1.45 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 22.22 | 0.00 |
Alpex Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.